Articles

Fluorescein angiography (FA) remains a valuable tool for monitoring anti-VEGF drugs after intravitreal injections, however, optical coherence tomography (OCT) is becoming and increasingly popular method.

A clinical trial of an electronic subretinal prosthesis has successfully allowed blind patients to recover some perception of single and multiple phosphenes, as well as horizontal and vertical lines.

Blue-blocking intraocular lenses (IOLs) offer no advantages to the eye and could actually cause health problems such as insomnia and depression.

Although femtosecond lasers offer a strong alternative to microkeratomes, they are not suitable for every situation, according to Theo Seiler, MD.

Product Watch

This year, from the 8th to 12th September, Stockholm will be playing host to the 25th Congress of the European Society for Cataract and Refractive Surgeons (ESCRS). More than 5,000 delegates from all around the world are expected to attend what is Europe's largest ophthalmic conference and exhibition. Attendees will be able to choose from between 100 courses, more than 20 symposia, in excess of 600 free papers and almost the same number of posters, as well as perusing the stands at the exhibition.

Over the past five years, we have successfully performed oculoplastic surgery on several hundred patients at the Belgian Ocular Laser Center (BOLC; www.BOLC.org) in Ghent, Belgium and, during this time, I have found the CO2 laser to provide an excellent alternative to the scalpel for treating the eyelids. Finally, we can offer bloodless surgery and improved outcomes.

Allergan pulled up by FDA; AMO makes a move on B&L; Opko snags Ophthalmic Technologies; Alcon sets its sights on WaveLight; B&L to sue Alcon; Ellex launches SLT website

It's that time of year again and it seems like only yesterday when we were gearing up for the annual congress of the ESCRS in London. Now the European society is taking us to the Swedish capital city, Stockholm, for its annual event.

Bevacizumab: less effective against larger lesions; New supranational European society; Happy 50th birthday SOE; Blue-blocking IOLs damage health; 3-D test identifies early stage glaucoma; A new way of tackling ROP; Femtosecond not always appropriate; High pulse pressure linked to OAG; Stem cell project to cure AMD underway; OCT increasingly popular for anti-VEGF monitoring; Glaucoma nano-treatment on the horizon; Lucky for some: the 13th LCA gene; Community optometrists able to diagnose glaucoma accurately; Coffee may prevent blepharospasm

The practice of treating angle closure glaucoma (ACG) varies widely across the United Kingdom, according to a poster presented at the 8th congress of the European Glaucoma Society (EGS), held June 1–6 in Berlin.

Sirion Therapeutics has initiated two new Phase III clinical studies for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).

The British intraocular lens (IOL) manufacturer, Rayner Intraocular Lenses, has received pre-market approval (PMA) for its C-flex lens from the FDA making it the first non-US IOL to receive FDA approval in twenty years.

Ellex Medical Lasers has received FDA 510(k) approval to market the Ellex 30XL laser slit lamp.

Novagali Pharma's Investigational New Drug Application (IND) to conduct a pivotal Phase III clinical trial of its dry eye candidate, Nova22007, has been granted by the FDA.

QLT has announced that the Committee for Medicinal Products for Human Use (CHMP) will recommend to the European Commission that the occult indication for Visudyne be removed from the product's European label.

ISTA Pharmaceuticals has withdrawn its marketing authorization application for Vitragen.

Medennium has obtained CE mark clearance to market its photochromic intraocular lens (IOL), Aurium in Europe, making it the first lens of its kind to be introduced to the cataract lens market.

The US FDA has approved wavefront-guided and mixed astigmatism indications for WaveLight's Allegretto Wave Eye-Q system.

Neurotech Pharmaceuticals has begun enrolment for two Phase II/III clinical trials of NT-501; it's lead Encapsulated Cell Technology (ECT) product for the treatment for retinitis pigmentosa (RP).

Alimera Sciences has announced that enrolment for its Phase III global clinical trial, FAME (Fluocinolone Acetonide in Diabetic Macular Edema), has exceeded 50%.

CoMentis (formerly Athenagen) has initiated a Phase II trial of ATG3, a topical eye drop therapy for the treatment of neovascular age-related macular degeneration (AMD).

The FDA has approved InSite Vision's New Drug Application (NDA) for AzaSite (azithromycin 1%) for the treatment of bacterial conjunctivitis.

ISTA Pharmaceuticals has received a not approvable letter from the FDA relating to its New Drug Application (NDA) for T-Pred (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension).

Aspheric-based treatments with the SCHWIND ESIRIS excimer laser and ORK-CAM software offer high predictability, increases in visual acuity (VA) and no induction of aberrations.

Therapeutic interventions, in particular for neovascular age-related macular degeneration (AMD) offer a better degree of value than any other treatment right across the field of healthcare.

Cup-to-disc ratios and visual field evaluations using telemedicine-friendly devices are the most useful tools for glaucoma screening.

Carl Zeiss Meditec has united its sales and marketing activities in Germany.

Optical coherence tomography (OCT) is a useful tool for determining when re-treatments with ranibizumab are required in patients with neovascular age-related macular degeneration (AMD).

Optical coherence tomography (OCT) is an effective screening tool for wet age-related macular degeneration (AMD).